Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1135 • 2019 ACR/ARP Annual Meeting
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Elena Myasoedova¹, Cynthia Crowson ², Rachel Giblon ¹, Kathleen McCarthy-Fruin ¹, Daniel Schaffer ¹, Kerry Wright ¹, Eric Matteson ³ and John Davis ¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: Flares in rheumatoid arthritis (RA) are common. The shortage of readily available specialized care may hinder early detection and timely management of RA flares.…
Abstract Number: 1336 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis
Daniel Aletaha¹, Ruta Sawant ², Patrick Zueger ³, Erin Cook ⁴, Fan Mu ⁴, Vishvas Garg ² and Keith A. Betts ⁴, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs have demonstrated efficacy for the treatment of rheumatoid arthritis (RA) in clinical trials; however, real-world evidence on…
Abstract Number: 1364 • 2019 ACR/ARP Annual Meeting
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Yael Ross¹, Madhavi Siddhanthi ², Lewis VanBrackle ³, David Carpenter ⁴, Aishwarya Rallabhandy ⁵ and Mohammad Kamran ², ¹WellStar Kennestone regional medical center, Atlanta, GA, ²WellStar Medical Group, Marietta, GA, ³Kennesaw State University, Kennesaw, ⁴WellStar Kennestone regional medical center, Marietta, ⁵High School, Marietta
Background/Purpose: The goal for treatment of RA is to obtain low disease activity for better outcomes. In order to achieve low disease activity, it is…
Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Vivian Bykerk¹, Wenhui Wei ², Susan Boklage ², Toshio Kimura ², Stefano Fiore ³ and Gregory St John ⁴, ¹Hospital for Special Surgery, New York City, NY, ²Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
Abstract Number: 1428 • 2019 ACR/ARP Annual Meeting
Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta ², Xiuying Li ², Edward Keystone ¹, Claire Bombardier ² and And Other OBRI Investigators ², ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug which can be used as an alternative to biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid…
Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Kenneth Saag¹, Michele McDermott ², Jonathan Adachi ³, Willem Lems ⁴, Nancy Lane ⁵, Piet Geusens ⁶, Peter Butler ², Li Chen ², Daria Crittenden ², Robin Dore ⁷ and Stanley Cohen ⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴VU University Medical Centre, Amsterdam, Netherlands, ⁵University of California at Davis Medical Center, Sacramento, CA, ⁶Maastricht University, Maastricht, Netherlands, ⁷Robin K Dore Inc, Tustin, CA, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…
Abstract Number: 1960 • 2019 ACR/ARP Annual Meeting
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Vivian Kawai¹, Mingjian Shi ¹, Qiping Feng ², Cecilia Chung ¹, Ge Liu ², Nancy Cox ², Dan Roden ², C. Michael Stein ¹ and Jonathan Mosley ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is associated with increased risk of cardiovascular disease, cardiometabolic disorders, and autoimmune disease. Thus, we…
Abstract Number: 2096 • 2019 ACR/ARP Annual Meeting
An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients
Valeria Valerio¹, Maria Bazan ¹, Mianbo Wang ², Bruce Mazer ¹, Elizabeth M. Hazel ³, Christian Pineau ⁴, Sasha Bernatsky ⁵, Brian Ward ⁶ and Ines Colmegna ⁶, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University Health Center, Montreal, Canada, ⁶McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Annual vaccination with inactivated influenza vaccine is recommended for adults with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Despite this, influenza immunization coverage…
Abstract Number: 2261 • 2019 ACR/ARP Annual Meeting
Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis
Marisel Vanesa Bejarano¹, Anastasia Secco ², Marta mamani ², Felix Romanini ² and Natalia Tamborenea ³, ¹Hospital Bernardino Rivadavia, Caba, Buenos Aires, Argentina, ²Hospital Rivadavia, Caba, Buenos Aires, Argentina, ³Hospital Rivadavia, Buenos Aires, Buenos Aires, Argentina
Background/Purpose: There is growing evidence that complex interactions between individual's genetic susceptibility, immunological processes, and environmental factors such as stress , increase the risk of…
Abstract Number: 2316 • 2019 ACR/ARP Annual Meeting
National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014
Shraddha Jatwani¹, Karan Jatwani ², Bikramjit Bindra ³ and Karan Chugh ¹, ¹St. Vincent Evansville, Evansville, ²Mount Sinai West - St Luke’s Hospital, New York, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Rheumatoid arthritis (RA) has been associated with increased cardiovascular mortality. More intensive treatment with a focus on “treat to target” strategies are being developed,…
Abstract Number: 2335 • 2019 ACR/ARP Annual Meeting
Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models
Hitomi Kobayashi¹, Isamu Yokoe ², Yasuyuki Kobayashi ³, Eichi Takaya ⁴, Atsuma Nishiwaki ¹, Kaita Sugiyama ¹, Noboru Kitamura ¹, Masaki Haraoka ³ and Masami Takei ¹, ¹Nihon University School of Medicine, Tokyo, Japan, ²Kyoundo Hospital, Tokyo, Japan, ³St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Graduate School, Keio University, Tokyo, Japan
Background/Purpose: Cardiac involvements cause of morbidity and mortality globally in rheumatoid arthritis (RA). Myocardial dysfunction may arise from a number of distinct processes, including myocardial…
Abstract Number: 2359 • 2019 ACR/ARP Annual Meeting
High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
Ori Elkayam ¹, Merav Lidar ², Tatiana Reitblat ³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Odelia Kakakian ¹, Tanya Meshiach ⁵, Ronit Almog ⁶ and Ofir Elalouf¹, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶the7Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel
Background/Purpose: The primary objective was to evaluate the effect of body mass index (BMI) on tumor necrosis factor α (TNF-α) blockers (including etanercept, infliximab, adalimumab…
Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Jesus Tornero¹, Mercedes Alperi-López ², Ivan Castellvi ³, Juan José de Agustín de Oro ⁴, Alejandro Escudero ⁵, Rosario Garcia-Vicuña ⁶, Miguel Angel González-Gay ⁷, Cristina Hidalgo ⁸, Esteban Rubio ⁹, Raimon Sanmarti ¹⁰, Núria Casamira ¹¹ and Jaime Calvo-Alen ¹², ¹Hospital de Guadalajara, Guadalajara, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Medical Department, Gebro Pharma S.A., Barcelona, Spain, ¹²Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
Abstract Number: 2764 • 2019 ACR/ARP Annual Meeting
Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Medication adherence is instrumental for the successful management of rheumatoid arthritis (RA) to a goal of remission. Awareness of medication necessity and concerns regarding…
Abstract Number: 2858 • 2019 ACR/ARP Annual Meeting
The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
Chenyang Lu ¹, Phillip Campbell ¹, Jonatan Hervoso ², Stephanie Rasmussen ², Wenyi Fu ², Jeffrey Ruth ², David Fox ³ and M Amin⁴, ¹the University of Michigan, Ann Arbor, MI, ²the University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disorder characterized by synovial hyperplasia, inflammatory cell infiltration and pannus formation. We have shown that soluble CD13 (sCD13)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].